Dr. Min S. Kang, MD

Dr. Kang practices at American Oncology Partners PA in Olympia, Washington.

Dr. Kang's NPI, 1457358749, was assigned on July 1, 2005. Dr. Kang graduated from Ohio State University College of Medicine in 1991. Dr. Kang holds Washington license MD00035445.

Dr. Kang's primary practice is American Oncology Partners PA, at 420 McPhee SW Rd, Olympia, WA 98502 in Thurston County. The practice phone is (614) 383-6000.

Dr. Kang's primary practice is American Oncology Partners PA in Olympia, Washington. Dr. Kang is also affiliated with Providence St. Peter Hospital. The medical group on file is Zangmeister Cancer Center. Dmand AI also links Dr. Kang to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kang practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kang is licensed in Washington.

CMS data shows 29,603 Medicare services from Dr. Kang across 41 procedure codes in 2024, for 632 Medicare patients. Medicare paid $620,489 for them.

CMS counts 632 Medicare patients who saw Dr. Kang in 2024. The largest group is 75 to 84, with 301 patients. 72% of them have high blood pressure, and 68% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kang's median patient age at 74, with 57% women.

In 2024, Dr. Kang wrote 967 Medicare Part D claims for 170 patients. 75% of them were for generic drugs. CMS names the drug for 630 of them, across 33 drugs with 11 or more claims each, at $1,477,419 in total drug cost. In 2023, CMS named 910 claims across 34 drugs.

Dr. Kang accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Kang, published from 2012 to 2025. 2013 was the busiest year, with 4. The most frequent topics are Alzheimer Disease, tau Proteins and Amyloid beta-Peptides. Dr. Kang has published most often in medRxiv. Dr. Kang's most frequent co-authors are Lawrence S. Honig, MD, PhD, Richard Mayeux, MD and Rafael Antonio Lantigua, MD.

CMS Open Payments shows 185 general payments to Dr. Kang from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. TESARO, Inc. paid the most, $10,663.

Dr. Kang graduated from Ohio State University College of Medicine in 1991.